Peijia Medical Ltd. (DE:4WO)
FRANKFURT:4WO
4WO Stock Chart & Stats
€0.66
>-€0.01(-1.71%)
At close: 4:00 PM EST
€0.66
>-€0.01(-1.71%)
Day’s Range― - ―
52-Week Range€0.41 - €1.01
Previous CloseN/A
Volume0.00
Average Volume (3M)42.00
Market Cap
€302.49M
Enterprise Value€2.21B
Total Cash (Recent Filing)€610.52M
Total Debt (Recent Filing)€434.22M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding674,736,940
10 Day Avg. Volume128
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio2.00
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.15Price Target Upside74.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€97.43M
Bulls Say, Bears Say
Bulls Say
High Gross Margins (~67%)Sustained gross margins near 67% indicate strong per‑unit economics typical of implantable devices. This pricing power and product cost structure create durable margin upside as fixed costs are leveraged, improving the path to profitability over months.
Meaningful Multi‑year Revenue ExpansionThe company's revenue has scaled materially over multiple years, showing commercial traction in its target therapies. Multi‑year adoption trends are durable for medical devices, supporting steady top‑line growth and potential operating leverage as procedure volumes rise.
Specialized Product Focus (structural Heart & Neurovascular)A concentrated product set in structural heart and neurovascular devices creates a clinical and regulatory moat. High barriers (regulatory, clinical training, hospital purchasing) and recurring consumables foster sticky customer relationships and sustainable market positioning over time.
Bears Say
Persistent Unprofitability (net Margin ~-29%)Despite revenue growth and healthy gross margins, operating losses and a -29% net margin persist. Continued unprofitability limits reinvestment, raises financing needs, and increases execution risk until margins convert to sustained positive operating earnings.
Negative Operating And Free Cash FlowMaterial negative OCF and ~-325M FCF in 2025 means the business is burning cash and depends on external funding. Weak cash conversion constrains commercialization, R&D and capital allocation, raising dilution and execution risk over the medium term.
Negative Return On Equity (ROE ~-11%)A negative ROE indicates the company is destroying shareholder capital rather than generating returns. Persistent negative returns can erode equity, deter investors, and make future fundraising more dilutive or costly if profitability is not achieved.
Peijia Medical Ltd. News
4WO FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was €0.41 and its highest was €1.01 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is €302.49M.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 71 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Mar 25, 2026. The company reported -€0.024 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.024.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Undervalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 674,736,940 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -€0.024 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.586%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in DE:4WO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
4WO Stock 12 Month Forecast
Average Price Target
€1.15
▲(74.32% Upside)
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---